Online inquiry

IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13854MR)

This product GTTS-WQ13854MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets GCGR gene. The antibody can be applied in Type 2 diabetes (T2 DM) research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Homo sapiens
RefSeq NM_000160.5
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 2642
UniProt ID P47871
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-GCGR, REGN-1193(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13854MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ14026MR IVTScrip™ mRNA-Anti-IL33, REGN-3500(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) mRNA REGN-3500
GTTS-WQ15278MR IVTScrip™ mRNA-Anti-EGFR, Theraloc(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA Theraloc
GTTS-WQ13022MR IVTScrip™ mRNA-Anti-IFNAR, Peg-IFNA2 R23(Cap 0, 2-Thio-UTP, 30 nt-poly(A)) mRNA Peg-IFNA2 R23
GTTS-WQ13491MR IVTScrip™ mRNA-Anti-IgG-Fc, PRTX-100(Cap 1, 5-Methyl-CTP, 120 nt-poly(A)) mRNA PRTX-100
GTTS-WQ3302MR IVTScrip™ mRNA-Anti-lukG&lukH, ASN-100(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 30 nt-poly(A)) mRNA ASN-100
GTTS-WQ9071MR IVTScrip™ mRNA-Anti-IGF1R, IMC-A12(Cap 0, 5-Methoxy-UTP, 120 nt-poly(A)) mRNA IMC-A12
GTTS-WQ12354MR IVTScrip™ mRNA-Anti-EGFR, N63Ab(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA N63Ab
GTTS-WQ8996MR IVTScrip™ mRNA-Anti-IL13, IMA-638(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA IMA-638
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW